| A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy (NCT01661270) | Sanofi | 2012-07-01 |
| Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients (NCT01909830) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2012-07-01 |
| Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (NCT01640444) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2012-07-01 |
| Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen (NCT01571284) | Sanofi | 2012-05-30 |
| A Study of Famitinib in Patients With Advanced Colorectal Cancer (NCT01762293) | Jiangsu HengRui Medicine Co., Ltd. | 2012-04-01 |
| Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (NCT01483027) | Boston Scientific Corporation | 2012-01-01 |
| Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer (NCT01471353) | University of Florida | 2011-11-01 |
| Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 (NCT01468623) | Myriad Genetic Laboratories, Inc. | 2011-09-01 |
| Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab (NCT01382407) | Rambam Health Care Campus | 2011-07-01 |
| Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer (NCT01298570) | UNC Lineberger Comprehensive Cancer Center | 2011-04-07 |
| FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema (NCT01315990) | Dr. Carl Schimanski | 2011-01-01 |
| Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer (NCT01317433) | Institut Cancerologie de l'Ouest | 2010-12-29 |
| Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC (NCT01249638) | Ludwig-Maximilians - University of Munich | 2010-12-01 |
| Combined Anticancer Treatment of Advanced Colon Cancer (NCT01540344) | University of Regensburg | 2010-10-01 |
| Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer (NCT01053013) | The Rogosin Institute | 2010-04-15 |
| First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer (NCT01163396) | Gruppo Oncologico del Nord-Ovest | 2007-07-01 |
| Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma (NCT00442637) | Dutch Colorectal Cancer Group | 2007-01-01 |
| PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome. (NCT00741481) | Jules Bordet Institute | 2006-06-01 |
| Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases. (NCT05273489) | Hospital Maciel | 2004-01-01 |
| Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer (NCT02286492) | Taiho Oncology, Inc. | |